October 6, 2026
Bonus Content: Vaxcyte Surges 50%-Plus: What VAX-31’s Phase 3 Win Means for Pfizer and Merck
Dear reader,
Most investors wait for the government press conference.
I follow the money before the cameras show up.
And the money trail now leads straight to one tiny nickel stock.
Its U.S. platform has already been selected for $135.4 million in disclosed federal grants: $114.8 million tied to a domestic processing facility and another $20.6 million supporting exploration in Minnesota and Michigan.
That is not a prediction. That’s money already disclosed.
The next step is my forecast: I believe Washington could eventually go further and take an equity stake.
It may never happen. But the U.S. has already shown it is willing to put taxpayer capital directly into strategic mineral companies. And this company now controls the only primary nickel mine operating in America.
Meanwhile, Tesla has locked in a six-year supply agreement, and America remains dangerously exposed to foreign nickel supply.
Russia, China, and Indonesia have leverage because the United States allowed its domestic pipeline to wither.
This little company is one of the few credible ways to fight back.
That’s why I bought 10,000 shares before any equity announcement.
I am not promising Washington will buy in. I am saying the grants, the operating mine, the Tesla agreement, and the strategic pressure form a setup I refuse to ignore.
Click here to learn more about the $5 nickel stock I believe Washington could target next.
Yours for peace, prosperity, and liberty, AEIOU,
Dr. Mark Skousen
Macroeconomic Strategist, The Oxford Club
P.S. Washington has already backed this platform with $135.4 million in disclosed grants.
If an equity stake comes next, I believe a stock this small could move violently.
I refuse to wait for the press conference.
Click here to reveal details on what I bought before Washington makes its next move.
Vaxcyte Surges 50%-Plus: What VAX-31’s Phase 3 Win Means for Pfizer and Merck
Analyst Targets
- Jefferies — Buy, $146 target; analyst Roger Song called the data a “blue-sky” scenario that exceeds management’s own expectations and positions VAX-31 for the lion’s share of a growing adult market
- Mizuho — Buy, $163 target; described the readout as “very clean” and near-ideal, arguing best-in-class potential in an $8 billion market is now difficult to dispute
- Guggenheim — Buy, target raised to $125 from $116; named Vaxcyte a top pick and said the readout sets up clear commercial leadership
- Needham — Buy, target raised to $122 from $110
- BTIG — Buy, $89 target reiterated
What Happened
On October 5, Vaxcyte shares surged approximately 32% in early trading following the announcement of positive topline results from its Phase 3 OPUS-1 trial for the 31-valent pneumococcal conjugate vaccine, VAX-31. The move accelerated intraday. Shares climbed about 50% in early trading.
Pre-market saw an even wider swing: Vaxcyte’s stock opened at $87.21 on October 5, a 54.4% rise from the October 2 close of $56.48.
That kind of gap on a Monday open does not happen on a mildly positive readout. The broader market offered no tailwind, with the S&P 500, Dow Jones, and Nasdaq all modestly lower on the day, underscoring that the move is entirely driven by company-specific news. The move was further amplified by a short squeeze dynamic, as short interest in the stock had been running around the low teens as a percentage of float heading into the readout, a level that historically accelerates upside moves when binary clinical events resolve favorably.
The Numbers from OPUS-1
The OPUS-1 trial dosed 4,049 participants. VAX-31 met all prespecified co-primary immunogenicity endpoints, with all 28 serotypes shared with Pfizer’s Prevnar 20 and/or Merck’s Capvaxive clearing the noninferiority threshold, while the three serotypes unique to VAX-31 and cross-reactive serotype 20B achieved superiority.
Jefferies noted that VAX-31 cleared a stricter noninferiority threshold than the historical standard used for approved pneumococcal vaccines. The broker said there were no formal noninferiority misses against the shared serotypes at the stricter threshold, compared with about three potential misses it had modelled. That context matters: some Wall Street investors had grown skeptical of VAX-31’s prospects after Vaxcyte narrowed timing guidance in early September for when OPUS-1 topline data would arrive. The clean sweep erased that discount entirely.
VAX-31 was well tolerated and demonstrated a safety profile similar to Pfizer’s and Merck’s approved vaccines across all ages studied.
Why Pfizer and Merck Should Pay Attention
Vaxcyte says VAX-31 could protect against about 95% of invasive disease in adults 50 and older and add incremental coverage of 13% to 36% of invasive cases and 19% to 31% of pneumococcal pneumonia versus current options. That is not a marginal improvement; it is the argument for switching the entire adult market.
Pfizer and Merck dominate the adult U.S. conjugate market today. Merck reported Capvaxive sales of $142 million in Q1 2026, up 31% year over year. Pfizer’s Prevnar franchise has been a multi-billion-dollar product family for years. A credible 31-valent entrant, one that just cleared its primary Phase 3 immunogenicity endpoints, changes the math for those revenue streams by the time a BLA lands.
BTIG noted the robust response to serotype 4 as a key driver of potential future uptake, as its omission in PCV21 has raised concerns among key opinion leaders. Physicians who have had to choose between Prevnar 20 and Capvaxive because no single shot covered everything now have a third option on the horizon that covers more ground than either.
Forward Scenarios
Bull: OPUS-2 and OPUS-3 data in H1 2027 replicate OPUS-1 cleanly. Analysts estimate the stock could rise another 50% to 100%, while Vaxcyte has said it expects OPUS-2 and OPUS-3 results in the first half of 2027, to be followed by a manufacturing consistency study, as the company works toward a planned BLA submission. Infant Phase 2 data by the first half of 2027 opens a second, larger indication. VAX-31 takes dominant adult share in a market Jefferies sizes at $3 billion to over $6 billion for the adult segment alone.
Base: BLA submission proceeds after the OPUS-2 and OPUS-3 readouts and a manufacturing consistency study, with approval timing dependent on regulators and manufacturing execution. VAX-31 captures meaningful but not dominant adult market share, coexisting with Prevnar 20 and Capvaxive on formularies. Vaxcyte trades in the Mizuho target range near $90 to $100 as the pipeline matures.
Bear: OPUS-2 or OPUS-3 surfaces unexpected noninferiority misses. Manufacturing scale-up delays the BLA. Competition from next-generation Pfizer or Merck formulations compresses the addressable premium.
Technical Overlay
Vaxcyte shares jumped sharply Monday, taking the stock above a prior 52-week high near $65. The gap open above $87 is now the key support reference; any fill of that gap would signal the market is reconsidering the trial’s commercial implications rather than just celebrating the binary outcome. Resistance sits at the Jefferies $146 and Mizuho $163 targets, both of which require OPUS-2 and OPUS-3 confirmation before becoming achievable.
What Investors Should Watch
- OPUS-2 and OPUS-3 readouts, H1 2027: The pivotal confirmatory data that determines BLA viability
- Infant Phase 2 data, in H1 2027: Opens a structurally larger market; success here would justify a materially higher valuation
- Pfizer and Merck response: Watch for accelerated higher-valency development programs or pricing strategy shifts in the adult market
- Analyst target revisions: Several firms have yet to update; a cluster of upgrades would signal broader institutional conviction
- Cash runway: Vaxcyte held approximately $2.8 billion between cash and investments as of June 30, 2026, providing substantial flexibility to fund operations through key Phase 3 and manufacturing milestones
Bottom Line
OPUS-1 did what bulls needed and then some. The trial was structured as a head-to-head against both approved market leaders, VAX-31 cleared noninferiority across the shared serotypes at a tighter threshold than prior standards, and it posted superiority on the strains only it covers. That is the cleanest possible Phase 3 immunogenicity outcome for a challenger vaccine. The question now is not whether VAX-31 works. It is whether Vaxcyte can replicate the result in two more trials, scale manufacturing, and reach physicians before Pfizer or Merck moves the goalposts with their own next-generation formulations. Those answers arrive in 2027.
